Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Risk and Volatility

Cytokinetics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.81, suggesting that its share price is 281% more volatile than the S&P 500.

Insider & Institutional Ownership

82.5% of Inhibrx Biosciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cytokinetics and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Analyst Ratings

This is a summary of current ratings and price targets for Cytokinetics and Inhibrx Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	19	0	2.86
Inhibrx Biosciences	1	2	2	1	2.50

Cytokinetics presently has a consensus target price of $105.44, suggesting a potential upside of 72.21%. Inhibrx Biosciences has a consensus target price of $197.50, suggesting a potential upside of 111.50%. Given Inhibrx Biosciences’ higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Cytokinetics.

Earnings & Valuation

This table compares Cytokinetics and Inhibrx Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04 million	86.54	-$784.96 million	($7.22)	-8.48
Inhibrx Biosciences	$1.30 million	1,057.35	-$140.05 million	($8.88)	-10.52

Inhibrx Biosciences has lower revenue, but higher earnings than Cytokinetics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Summary

Inhibrx Biosciences beats Cytokinetics on 8 of the 15 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.